Filing Flows › Connect Biopharma Holdings (CNTB) › R&D spending
Connect Biopharma Holdings (CNTB) R&D spending by quarter
Connect Biopharma Holdings' R&D spending was $16.3M in Q2 2026 (second quarter 2026), +8% from Q1 2026. Over the last 5 quarters it ranged from $6.2M (Q4 2024) to $16.3M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $16.3M | +8% | +85% |
| Q1 2026 | $15.0M | +35% | — |
| Q3 2025 | $11.1M | +27% | — |
| Q2 2025 | $8.8M | +41% | — |
| Q4 2024 | $6.2M | — | — |
Q2 2026 at a glance
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Connect Biopharma Holdings' R&D spending?
Connect Biopharma Holdings' R&D spending was $16.3M in Q2 2026 (second quarter 2026), +8% from Q1 2026.
How has Connect Biopharma Holdings' R&D spending changed?
Over the last 5 quarters it ranged from $6.2M (Q4 2024) to $16.3M (Q2 2026).
Q2 2026 results → · How Connect Biopharma Holdings makes money →